Preventing α-synuclein aggregation: The role of the small heat-shock molecular chaperone proteins

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1830-1843

  Cox, Dezerae ^a   Carver, John A ^b   Ecroyd, Heath ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Amyloid; Parkinson's disease; Protein aggregation; Proteostasis; Synuclein; B crystallin

Indexed keywords

ALPHA CRYSTALLIN; ALPHA SYNUCLEIN; HEAT SHOCK PROTEIN 20; HEAT SHOCK PROTEIN 22; HEAT SHOCK PROTEIN 27; SMALL HEAT SHOCK PROTEIN; CHAPERONE; HEAT SHOCK PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATOMIC FORCE MICROSCOPY; CYTOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEWY BODY; LIPID HOMEOSTASIS; MACROAUTOPHAGY; MICROAUTOPHAGY; NEURITE; NONHUMAN; PARKINSON DISEASE; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; NEURITIS;

AMYLOID; PARKINSON'S DISEASE; PROTEIN AGGREGATION; PROTEOSTASIS; Α-SYNUCLEIN; ΑB-CRYSTALLIN;

ALPHA-SYNUCLEIN; ANIMALS; HEAT-SHOCK PROTEINS, SMALL; HUMANS; MOLECULAR CHAPERONES; NEURODEGENERATIVE DISEASES;

EID: 84904431211     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.06.024     Document Type: Review

References (231)

1. Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
2. Aguzzi A., O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 2010, 9:237-248.
3. Martí M.J., Tolosa E., Campdelacreu J. Clinical overview of the synucleinopathies. Mov. Disord. 2003, 18:21-27.
4. Saiki S., Sato S., Hattori N. Molecular pathogenesis of Parkinson's disease: update. J. Neurol. Neurosurg. Psychiatry 2012, 83:430-436.
5. Shulman J.M., De Jager P.L., Feany M.B. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. Mech. 2011, 6:193-222.
6. Wenning G.K., Stefanova N., Jellinger K.A., Poewe W., Schlossmacher M.G. Multiple system atrophy: a primary oligodendrogliopathy. Ann. Neurol. 2008, 64:239-246.
7. Meeus B., Theuns J., Van Broeckhoven C. The genetics of dementia with lewy bodies: what are we missing?. Arch. Neurol. 2012, 69:1113-1118.
8. Ozawa T. Pathology and genetics of multiple system atrophy: an approach to determining genetic susceptibility spectrum. Acta Neuropathol. 2006, 112:531-538.
9. Jäättelä M. Heat shock proteins as cellular lifeguards. Ann. Med. 1999, 31:261-271.
10. Carver J.A., Lindner R.A., Lyon C., Canet D., Hernandez H., Dobson C.M., Redfield C. The interaction of the molecular chaperone α-crystallin with unfolding α-lactalbumin: a structural and kinetic spectroscopic study. J. Mol. Biol. 2002, 318:815-827.
11. Rekas A., Adda C.G., Aquilina J.A., Barnham K.J., Sunde M., Galatis D., Williamson N.A., Masters C.L., Anders R.F., Robinson C.V., Cappai R., Carver J.A. Interaction of the molecular chaperone αB-crystallin with α-synuclein: effects on amyloid fibril formation and chaperone activity. J. Mol. Biol. 2004, 340:1167-1183.
12. Binger K.J., Ecroyd H., Yang S., Carver J.A., Howlett G.J., Griffin M.D.W. Avoiding the oligomeric state: αB-crystallin inhibits fragmentation and induces dissociation of apolipoprotein C-II amyloid fibrils. FASEB J. 2012, 27:1214-1222.
13. Pivovarova A.V., Chebotareva N.A., Chernik I.S., Gusev N.B., Levitsky D.I. Small heat shock protein Hsp27 prevents heat-induced aggregation of F-actin by forming soluble complexes with denatured actin. FEBS J. 2007, 274:5937-5948.
14. Rekas A., Jankova L., Thorn D.C., Cappai R., Carver J.A. Monitoring the prevention of amyloid fibril formation by α-crystallin. FEBS J. 2007, 274:6290-6304.
15. Bruinsma I.B., Bruggink K.A., Kinast K., Versleijen A.A.M., Segers-Nolten I.M.J., Subramaniam V., Bea Kuiperij H., Boelens W., de Waal R.M.W., Verbeek M.M. Inhibition of alpha-synuclein aggregation by small heat shock proteins. Proteins Struct. Funct. Bioinform. 2011, 79:2956-2967.
16. Ebrahimi-Fakhari D., Saidi L.-J., Wahlster L. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies. Acta Neuropathol. Commun. 2013, 1:79.
17. Witt S. Molecular chaperones, alpha-synuclein, and neurodegeneration. Mol. Neurobiol. 2013, 47:552-560.
18. Dimant H., Ebrahimi-Fakhari D., McLean P.J. Molecular chaperones and co-chaperones in Parkinson disease. Neuroscientist 2012, 18:589-601.
19. Chaari A., Hoarau-Véchot J., Ladjimi M. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease. Int. J. Biol. Macromol. 2013, 60:196-205.
20. Wyatt A.R., Yerbury J.J., Ecroyd H., Wilson M.R. Extracellular chaperones and proteostasis. Annu. Rev. Biochem. 2013, 82:295-322.
21. Gidalevitz T., Prahlad V., Morimoto R.I. The stress of protein misfolding: from single cells to multicellular organisms. Cold Spring Harb. Perspect Biol. 2011, 3:a009704.
22. Yerbury J.J., Stewart E.M., Wyatt A.R., Wilson M.R. Quality control of protein folding in extracellular space. EMBO Rep. 2005, 6:1131-1136.
23. Chen S., Brown I.R. Neuronal expression of constitutive heat shock proteins: implications for neurodegenerative diseases. Cell Stress Chaperones 2007, 12:51-58.
24. Powers E.T., Morimoto R.I., Dillin A., Kelly J.W., Balch W.E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 2009, 78:959-991.
25. Anfinsen C.B., Haber E., Sela M., White F.H. The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain. Proc. Natl. Acad. Sci. U. S. A. 1961, 47:1309-1314.
26. Wright P.E., Dyson H.J. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 1999, 293:321-331.
27. Uversky V.N. Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 2002, 11:739-756.
28. Dunker A.K., Lawson J.D., Brown C.J., Williams R.M., Romero P., Oh J.S., Oldfield C.J., Campen A.M., Ratliff C.M., Hipps K.W., Ausio J., Nissen M.S., Reeves R., Kang C., Kissinger C.R., Bailey R.W., Griswold M.D., Chiu W., Garner E.C., Obradovic Z. Intrinsically disordered protein. J. Mol. Graph. Model. 2001, 19:26-59.
29. Radford S.E., Dobson C.M. From computer simulations to human disease: emerging themes in protein folding. Cell 1999, 97:291-298.
30. Trombetta E.S., Parodi A.J. Quality control and protein folding in the secretory pathway. Annu. Rev. Cell Dev. Biol. 2003, 19:649-676.
31. Hohfeld J., Cyr D.M., Patterson C. From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep. 2001, 2:885-890.
32. Hartl F.U. Molecular chaperones in cellular protein folding. Nature 1996, 381:571-580.
33. Hartl F.U., Bracher A., Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature 2011, 475:324-332.
34. Ellis R.J. Do molecular chaperones have to be proteins?. Biochem. Biophys. Res. Commun. 1997, 238:687-692.
35. Feder M.E., Hofmann G.E. Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Annu. Rev. Physiol. 1999, 61:243-282.
36. Sarkar S., Singh M.D., Yadav R., Arunkumar K.P., Pittman G. Heat shock proteins: molecules with assorted functions. Front. Biol. 2011, 6:312-327.
37. Hoffmann J.H., Linke K., Graf P.C., Lilie H., Jakob U. Identification of a redox-regulated chaperone network. EMBO J. 2004, 23:160-168.
38. Beissinger M., Buchner J. How chaperones fold proteins. Biol. Chem. 1998, 379:245-259.
39. Hubbard T.J.P., Sander C. The role of heat-shock and chaperone proteins in protein folding: possible molecular mechanisms. Protein Eng. 1991, 4:711-717.
40. Slepenkov S.V., Witt S.N. The unfolding story of the Escherichia coli Hsp70 DnaK: is DnaK a holdase or an unfoldase?. Mol. Microbiol. 2002, 45:1197-1206.
41. Rikhvanov E.G., Romanova N.V., Chernoff Y.O. Chaperone effects on prion and nonprion aggregates. Prion 2007, 1:217-222.
42. Schwartz A.L., Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 1999, 50:57-74.
43. Cook C., Stetler C., Petrucelli L. Disruption of protein quality control in Parkinson's disease. Cold Spring Harb. Perspect Biol. 2012, 2:a009423.
44. Kaushik S., Cuervo A.M. Chaperones in autophagy. Pharmacol. Res. 2012, 66:484-493.
45. Engelsman J., Keijsers V., de Jong W.W., Boelens W.C. The small heat shock protein αB-crystallin promotes FBX4-dependent ubiquitination. J. Biol. Chem. 2003, 278:4699-4704.
46. Carra S., Seguin S.J., Lambert H., Landry J. HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J. Biol. Chem. 2008, 283:1437-1444.
47. Ahner A., Gong X., Schmidt B.Z., Peters K.W., Rabeh W.M., Thibodeau P.H., Lukacs G.L., Frizzell R.A. Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier-dependent pathway. Mol. Biol. Cell 2013, 24:74-84.
48. Parcellier A., Gurbuxani S., Schmitt E., Solary E., Garrido C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem. Biophys. Res. Commun. 2003, 304:505-512.
49. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
50. Barral J.M., Broadley S.A., Schaffar G., Hartl F.U. Roles of molecular chaperones in protein misfolding diseases. Semin. Cell Dev. Biol. 2004, 15:17-29.
51. de Lau L.M.L., Breteler M.M.B. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
52. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
53. Massano J., Bhatia K.P. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb. Perspect Biol. 2012, 2:a008870.
54. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
55. Chaudhuri K.R., Healy D.G., Schapira A.H.V. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
56. Wakabayashi K., Tanji K., Mori F., Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007, 27:494-506.
57. Fink A.L. The aggregation and fibrillation of α-synuclein. Acc. Chem. Res. 2006, 39:628-634.
58. Spillantini M.G., Schmidt M.L., Lee V.M.Y., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
59. Pountney D., Treweek T.M., Chataway T., Huang Y., Chegini F., Blumbergs P., Raftery M., Gai W. αB-crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy. Neurotox. Res. 2005, 7:77-85.
60. Campbell B.C.V., McLean C.A., Culvenor J.G., Gai W.P., Blumbergs P.C., Jäkälä P., Beyreuther K., Masters C.L., Li Q.-X. The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 2001, 76:87-96.
61. Hashimoto M., Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 1999, 9:707-720.
62. Scherzer C.R., Grass J.A., Liao Z., Pepivani I., Zheng B., Eklund A.C., Ney P.A., Ng J., McGoldrick M., Mollenhauer B., Bresnick E.H., Schlossmacher M.G. GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10907-10912.
63. Barbour R., Kling K., Anderson J.P., Banducci K., Cole T., Diep L., Fox M., Goldstein J.M., Soriano F., Seubert P., Chilcote T.J. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 2008, 5:55-59.
64. Muchowski P.J., Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 2005, 6:11-22.
65. Maroteaux L., Campanelli J., Scheller R. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8:2804-2815.
66. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273:9443-9449.
67. Jenco J.M., Rawlingson A., Daniels B., Morris A.J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry 1998, 37:4901-4909.
68. Ueda K., Saitoh T., Mori H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-Aβ component of Alzheimer's disease amyloid. Biochem. Biophys. Res. Commun. 1994, 205:1366-1372.
69. Campion D., Martin C., Heilig R., Charbonnier F., Moreau V., Flaman J.M., Petit J.L., Hannequin D., Brice A., Frebourg T. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 1995, 26:254-257.
70. Halliday G.M., McCann H. Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms. Exp. Neurol. 2008, 209:12-21.
71. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
72. Tofaris G.K., Garcia Reitböck P., Humby T., Lambourne S.L., O'Connell M., Ghetti B., Gossage H., Emson P.C., Wilkinson L.S., Goedert M., Spillantini M.G. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1-120): implications for Lewy body disorders. J. Neurosci. 2006, 26:3942-3950.
73. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 1998, 436:309-312.
74. Tofaris G.K., Razzaq A., Ghetti B., Lilley K.S., Spillantini M.G. Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 2003, 278:44405-44411.
75. Bellucci A., Navarria L., Zaltieri M., Falarti E., Bodei S., Sigala S., Battistin L., Spillantini M., Missale C., Spano P. Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. J. Neurochem. 2011, 116:588-605.
76. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
77. Golbe L.I., Di Iorio G., Bonavita V., Miller D.C., Duvoisin R.C. A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol. 1990, 27:276-282.
78. Golbe L.I. The genetics of Parkinson's disease: a reconsideration. Neurology 1990, 40:7-16.
79. Zarranz J.J., Alegre J., Gómez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atarés B., Llorens V., Tortosa E.G., del Ser T., Muñoz D.G., de Yebenes J.G. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
80. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
81. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 2006, 7:306-318.
82. Wang W., Perovic I., Chittuluru J., Kaganovich A., Nguyen L.T.T., Liao J., Auclair J.R., Johnson D., Landeru A., Simorellis A.K., Ju S., Cookson M.R., Asturias F.J., Agar J.N., Webb B.N., Kang C., Ringe D., Petsko G.A., Pochapsky T.C., Hoang Q.Q. A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17797-17802.
83. Bartels T., Choi J.G., Selkoe D.J. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110.
84. Dettmer U., Newman A.J., Luth E.S., Bartels T., Selkoe D. In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J. Biol. Chem. 2013, 288:6371-6385.
85. Eliezer D., Kutluay E., Bussell R., Browne G. Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol. 2001, 307:1061-1073.
86. Fauvet B., Mbefo M.K., Fares M.-B., Desobry C., Michael S., Ardah M.T., Tsika E., Coune P., Prudent M., Lion N., Eliezer D., Moore D.J., Schneider B., Aebischer P., El-Agnaf O.M., Masliah E., Lashuel H.A. Alpha-synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 2012, 287:15345-15364.
87. Rochet J.-C., Conway K.A., Lansbury P.T. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein. Biochemistry 2000, 39:10619-10626.
88. Serpell L.C., Berriman J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4897-4902.
89. Uversky V.N. Neuropathology, biochemistry, and biophysics of α-synuclein aggregation. J. Neurochem. 2007, 103:17-37.
90. Wood S.J., Wypych J., Steavenson S., Louis J.-C., Citron M., Biere A.L. α-Synuclein fibrillogenesis is nucleation-dependent. J. Biol. Chem. 1999, 274:19509-19512.
91. Bhak G., Lee J.H., Hahn J.S., Paik S.R. Granular assembly of alpha-synuclein leading to the accelerated amyloid fibril formation with shear stress. PLoS ONE 2009, 4:e4177.
92. 19F NMR studies of α-synuclein conformation and fibrillation. Biochemistry 2009, 48:8578-8584.
93. Ono K., Ikeda T., Takasaki J.-i., Yamada M. Familial Parkinson disease mutations influence α-synuclein assembly. Neurobiol. Dis. 2011, 43:715-724.
94. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4:1318-1320.
95. Conway K.A., Harper J.D., Lansbury P.T. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39:2552-2563.
96. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
97. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Harper J.D., Williamson R.E., Lansbury P.T. Accelerated oligomerization by Parkinson's disease linked α-synuclein mutants. Ann. N. Y. Acad. Sci. 2000, 920:42-45.
98. Sellbach A.N., Boyle R.S., Silburn P.A., Mellick G.D. Parkinson's disease and family history. Parkinsonism Relat. Disord. 2006, 12:399-409.
99. Shtilerman M.D., Ding T.T., Lansbury P.T. Molecular crowding accelerates fibrillization of α-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?. Biochemistry 2002, 41:3855-3860.
100. Uversky V.N., Cooper E.M., Bower K.S., Li J., Fink A.L. Accelerated α-synuclein fibrillation in crowded milieu. FEBS Lett. 2002, 515:99-103.
101. Munishkina L.A., Cooper E.M., Uversky V.N., Fink A.L. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J. Mol. Recognit. 2004, 17:456-464.
102. Uversky V.N., Li J., Souillac P., Millett I.S., Doniach S., Jakes R., Goedert M., Fink A.L. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of α-synuclein assembly by β- and γ-synucleins. J. Biol. Chem. 2002, 277:11970-11978.
103. Hashimoto M., Rockenstein E., Mante M., Mallory M., Masliah E. β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-Parkinsonian factor. Neuron 2001, 32:213-223.
104. Breydo L., Wu J.W., Uversky V.N. α-Synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta-Mol. Basis Dis. 2012, 1822:261-285.
105. Rajagopalan S., Andersen J.K. Alpha synuclein aggregation: is the toxic gain of function responsible for neurodegeneration in Parkinson's disease?. Mech. Ageing Dev. 2001, 122:1499-1510.
106. Stefanis L. α-Synuclein in Parkinson's disease. Cold Spring Harb. Perspect Med. 2012, 2:a009399.
107. Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M.G., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
108. Welchko R., Leveque X., Dunbar G. Genetic rat models of Parkinson's disease. Park. Dis. 2012, 2012:128356. (Article ID).
109. Iwai A. Properties of NACP/α-synuclein and its role in Alzheimer's disease. Biochim. Biophys. Acta-Mol. Basis Dis. 2000, 1502:95-109.
110. Kaplan B., Ratner V., Haas E. Alpha-synuclein. J. Mol. Neurosci. 2003, 20:83-92.
111. Gibb W.R., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1988, 51:745-752.
112. Hindle J.V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161.
113. Gosavi N., Lee H.-J., Lee J.S., Patel S., Lee S.-J. Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 2002, 277:48984-48992.
114. Xu J., Kao S.-Y., Lee F.J.S., Song W., Jin L.-W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 2002, 8:600-606.
115. Gertz H.-J., Siegers A., Kuchinke J. Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. Brain Res. 1994, 637:339-341.
116. van der Putten H., Wiederhold K.-H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P.J.M., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 2000, 20:6021-6029.
117. Auluck P.K., Bonini N.M. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 2002, 8:1185-1186.
118. Auluck P.K., Chan H.Y.E., Trojanowski J.Q., Lee V.M.Y., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
119. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., Hetzer C., Loher T., Vilar M., Campioni S., Tzitzilonis C., Soragni A., Jessberger S., Mira H., Consiglio A., Pham E., Masliah E., Gage F.H., Riek R. In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
120. Conway K.A., Rochet J.-C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 2001, 294:1346-1349.
121. Mazzulli J.R., Mishizen A.J., Giasson B.I., Lynch D.R., Thomas S.A., Nakashima A., Nagatsu T., Ota A., Ischiropoulos H. Cytosolic catechols inhibit α-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 2006, 26:10068-10078.
122. Tsika E., Moysidou M., Guo J., Cushman M., Gannon P., Sandaltzopoulos R., Giasson B.I., Krainc D., Ischiropoulos H., Mazzulli J.R. Distinct region-specific α-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J. Neurosci. 2010, 30:3409-3418.
123. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283:29639-29643.
124. Glabe C. Amyloid oligomer structures and toxicity. Open Biol. 2009, 2:222-227.
125. Xue W.-F., Hellewell A.L., Gosal W.S., Homans S.W., Hewitt E.W., Radford S.E. Fibril fragmentation enhances amyloid cytotoxicity. J. Biol. Chem. 2009, 284:34272-34282.
126. Goldberg M.S., Lansbury P.T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?. Nat. Cell Biol. 2000, 2:115-119.
127. Tyedmers J., Mogk A., Bukau B. Cellular strategies for controlling protein aggregation. Nat. Rev. Mol. Cell Biol. 2010, 11:777-788.
128. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416:507-511.
129. Sirangelo I., Malmo C., Iannuzzi C., Mezzogiorno A., Bianco M.R., Papa M., Irace G. Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin mutant W7FW14F. J. Biol. Chem. 2004, 279:13183-13189.
130. Malisauskas M., Ostman J., Darinskas A., Zamotin V., Liutkevicius E., Lundgren E., Morozova-Roche L.A. Does the cytotoxic effect of transient amyloid oligomers from common equine lysozyme in vitro imply innate amyloid toxicity?. J. Biol. Chem. 2005, 280:6269-6275.
131. Bolognesi B., Kumita J.R., Barros T.P., Esbjorner E.K., Luheshi L.M., Crowther D.C., Wilson M.R., Dobson C.M., Favrin G., Yerbury J.J. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 2010, 5:735-740.
132. Cheon M., Chang I., Mohanty S., Luheshi L.M., Dobson C.M., Vendruscolo M., Favrin G. Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput. Biol. 2007, 3:1727-1738.
133. Kremer J.J., Pallitto M.M., Sklansky D.J., Murphy R.M. Correlation of β-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 2000, 39:10309-10318.
134. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.
135. Zhu M., Li J., Fink A.L. The association of α-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem. 2003, 278:40186-40197.
136. Invernizzi G., Papaleo E., Sabate R., Ventura S. Protein aggregation: mechanisms and functional consequences. Int. J. Biochem. Cell Biol. 2012, 44:1541-1554.
137. Cookson M.R., van der Brug M. Cell systems and the toxic mechanism(s) of α-synuclein. Exp. Neurol. 2008, 209:5-11.
138. Volles M.J., Lansbury P.T. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41:4595-4602.
139. Furukawa K., Matsuzaki-Kobayashi M., Hasegawa T., Kikuchi A., Sugeno N., Itoyama Y., Wang Y., Yao P.J., Bushlin I., Takeda A. Plasma membrane ion permeability induced by mutant α-synuclein contributes to the degeneration of neural cells. J. Neurochem. 2006, 97:1071-1077.
140. Cookson M.R. Alpha-synuclein and neuronal cell death. Mol. Neurodegener. 2009, 4.
141. Chu Y., Morfini G.A., Langhamer L.B., He Y., Brady S.T., Kordower J.H. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135:2058-2073.
142. Maries E., Dass B., Collier T.J., Kordower J.H., Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 2003, 4:727-738.
143. Lundblad M., Decressac M., Mattsson B., Björklund A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3213-3219.
144. Bellucci A., Navarria L., Zaltieri M., Missale C., Spano P. Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res. 2012, 1432:95-113.
145. Marques O., Outeiro T.F. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 2012, 3:e350.
146. Bellucci A., Zaltieri M., Navarria L., Grigoletto J., Missale C., Spano P. From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease. Brain Res. 2012, 1476:183-202.
147. McLean P.J., Kawamata H., Shariff S., Hewett J., Sharma N., Ueda K., Breakefield X.O., Hyman B.T. TorsinA and heat shock proteins act as molecular chaperones: suppression of α-synuclein aggregation. J. Neurochem. 2002, 83:846-854.
148. Uryu K., Richter-Landsberg C., Welch W., Sun E., Goldbaum O., Norris E.H., Pham C.T., Yazawa I., Hilburger K., Micsenyi M., Giasson B.I., Bonini N.M., Lee V.M., Trojanowski J.Q. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am. J. Pathol. 2006, 168:947-961.
149. Outeiro T.F., Klucken J., Strathearn K.E., Liu F., Nguyen P., Rochet J.-C., Hyman B.T., McLean P.J. Small heat shock proteins protect against α-synuclein-induced toxicity and aggregation. Biochem. Biophys. Res. Commun. 2006, 351:631-638.
150. Lowe J., Landon M., Pike I., Spendlove I., McDermott H., John Mayer R. Dementia with β-amyloid deposition: involvement of αB-crystallin supports two main diseases. Lancet 1990, 336:515-516.
151. Iwaki T., Wisniewski T., Iwaki A., Corbin E., Tomokane N., Tateishi J., Goldman J.E. Accumulation of alpha B-crystallin in central nervous system glia and neurons in pathologic conditions. Am. J. Pathol. 1992, 140:345-356.
152. Mizutani T., Inose T., Nakajima S., Kakimi S., Uchigata M., Ikeda K., Gambetti P., Takasu T. Familial parkinsonism and dementia with ballooned neurons, argyrophilic neuronal inclusions, atypical neurofibrillary tangles, tau-negative astrocytic fibrillary tangles, and Lewy bodies. Acta Neuropathol. 1997, 95:15-27.
153. Kampinga H., Hageman J., Vos M., Kubota H., Tanguay R., Bruford E., Cheetham M., Chen B., Hightower L. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009, 14:105-111.
154. Carra S., Rusmini P., Crippa V., Giorgetti E., Boncoraglio A., Cristofani R., Naujock M., Meister M., Minoia M., Kampinga H.H., Poletti A. Different anti-aggregation and pro-degradative functions of the members of the mammalian sHSP family in neurological disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013, 368.
155. Kulig M., Ecroyd H. The small heat-shock protein alphaB-crystallin uses different mechanisms of chaperone action to prevent the amorphous versus fibrillar aggregation of alpha-lactalbumin. Biochem. J. 2012, 448:343-352.
156. Basha E., O'Neill H., Vierling E. Small heat shock proteins and alpha-crystallins: dynamic proteins with flexible functions. Trends Biochem. Sci. 2012, 37:106-117.
157. Haslbeck M., Franzmann T., Weinfurtner D., Buchner J. Some like it hot: the structure and function of small heat-shock proteins. Nat. Struct. Mol. Biol. 2005, 12:842-846.
158. Sun Y., MacRae T. Small heat shock proteins: molecular structure and chaperone function. Cell. Mol. Life Sci. 2005, 62:2460-2476.
159. Hilton G.R., Lioe H., Stengel F., Baldwin A.J., Benesch J.L. Small heat-shock proteins: paramedics of the cell. Top. Curr. Chem. 2013, 328:69-98.
160. van Montfort R.L.M., Basha E., Friedrich K.L., Slingsby C., Vierling E. Crystal structure and assembly of a eukaryotic small heat shock protein. Nat. Struct. Mol. Biol. 2001, 8:1025-1030.
161. Stamler R., Kappe G., Boelens W., Slingsby C. Wrapping the alpha-crystallin domain fold in a chaperone assembly. J. Mol. Biol. 2005, 353:68-79.
162. Kim K.K., Kim R., Kim S.-H. Crystal structure of a small heat-shock protein. Nature 1998, 394:595-599.
163. Lindner R.A., Carver J.A., Ehrnsperger M., Buchner J., Esposito G., Behlke J., Lutsch G., Kotlyarov A., Gaestel M. Mouse Hsp25, a small heat shock protein. The role of its C-terminal extension in oligomerization and chaperone action. Eur. J. Biochem. 2000, 267:1923-1932.
164. 1H NMR spectroscopy of flexible C-terminal extensions in bovine lens α-crystallin. FEBS Lett. 1992, 311:143-149.
165. Giese K.C., Basha E., Catague B.Y., Vierling E. Evidence for an essential function of the N terminus of a small heat shock protein in vivo, independent of in vitro chaperone activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18896-18901.
166. Stromer T., Fischer E., Richter K., Haslbeck M., Buchner J. Analysis of the regulation of the molecular chaperone Hsp26 by temperature-induced dissociation: the N-terminal domain is important for oligomer assembly and the binding of unfolding proteins. J. Biol. Chem. 2004, 279:11222-11228.
167. Aquilina J.A., Watt S.J. The N-terminal domain of alphaB-crystallin is protected from proteolysis by bound substrate. Biochem. Biophys. Res. Commun. 2007, 353:1115-1120.
168. Peschek J., Braun N., Rohrberg J., Back K.C., Kriehuber T., Kastenmüller A., Weinkauf S., Buchner J. Regulated structural transitions unleash the chaperone activity of αB-crystallin. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3780-3789.
169. Jehle S., Rajagopal P., Bardiaux B., Markovic S., Kuhne R., Stout J.R., Higman V.A., Klevit R.E., van Rossum B.J., Oschkinat H. Solid-state NMR and SAXS studies provide a structural basis for the activation of alphaB-crystallin oligomers. Nat. Struct. Mol. Biol. 2010, 17:1037-1042.
170. Feil I.K., Malfois M., Hendle J., van der Zandt H., Svergun D.I. A novel quaternary structure of the dimeric α-crystallin domain with chaperone-like activity. J. Biol. Chem. 2001, 276:12024-12029.
171. Hochberg G.K., Ecroyd H., Liu C., Cox D., Cascio D., Sawaya M.R., Collier M.P., Stroud J., Carver J.A., Baldwin A.J., Robinson C.V., Eisenberg D.S., Benesch J.L., Laganowsky A. The structured core domain of alphaB-crystallin can prevent amyloid fibrillation and associated toxicity. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:1562-1570.
172. Benesch J.L.P., Ayoub M., Robinson C.V., Aquilina J.A. Small heat shock protein activity is regulated by variable oligomeric substructure. J. Biol. Chem. 2008, 283:28513-28517.
173. Van Montfort R., Slingsby C., Vierling E. Structure and function of the small heat shock protein/alpha-crystallin family of molecular chaperones. Adv. Protein Chem. 2002, 59:105-156.
174. Jehle S., Vollmar B.S., Bardiaux B., Dove K.K., Rajagopal P., Gonen T., Oschkinat H., Klevit R.E. N-terminal domain of αB-crystallin provides a conformational switch for multimerization and structural heterogeneity. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:6409-6414.
175. Ahmad M.F., Raman B., Ramakrishna T., Rao C.M. Effect of phosphorylation on αB-crystallin: differences in stability, subunit exchange and chaperone activity of homo and mixed oligomers of αB-crystallin and its phosphorylation-mimicking mutant. J. Mol. Biol. 2008, 375:1040-1051.
176. Bova M.P., Ding L.L., Horwitz J., Fung B.K.K. Subunit exchange of αA-crystallin. J. Biol. Chem. 1997, 272:29511-29517.
177. Bova M.P., Mchaourab H.S., Han Y., Fung B.K.K. Subunit exchange of small heat shock proteins: analysis of oligomer formation of alphaA-crystallin and Hsp27 by fluorescence resonance energy transfer and site-directed truncations. J. Biol. Chem. 2000, 275:1035-1042.
178. Lelj-Garolla B., Mauk A.G. Self-association and chaperone activity of Hsp27 are thermally activated. J. Biol. Chem. 2006, 281:8169-8174.
179. Haslbeck M., Walke S., Stromer T., Ehrnsperger M., White H.E., Chen S., Saibil H.R., Buchner J. Hsp26: a temperature-regulated chaperone. EMBO J. 1999, 18:6744-6751.
180. Chernik I.S., Panasenko O.O., Li Y., Marston S.B., Gusev N.B. pH-induced changes of the structure of small heat shock proteins with molecular mass 24/27kDa (HspB1). Biochem. Biophys. Res. Commun. 2004, 324:1199-1203.
181. Lindner R.A., Treweek T.M., Carver J.A. The molecular chaperone alpha-crystallin is in kinetic competition with aggregation to stabilize a monomeric molten-globule form of alpha-lactalbumin. Biochem. J. 2001, 354:79-87.
182. Stetler R.A., Gan Y., Zhang W., Liou A.K., Gao Y., Cao G., Chen J. Heat shock proteins: cellular and molecular mechanisms in the central nervous system. Prog. Neurobiol. 2010, 92:184-211.
183. Garrido C., Paul C., Seigneuric R., Kampinga H.H. The small heat shock proteins family: the long forgotten chaperones. Int. J. Biochem. Cell Biol. 2012, 44:1588-1592.
184. Klemenz R., Fröhli E., Steiger R.H., Schäfer R., Aoyama A. Alpha B-crystallin is a small heat shock protein. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3652-3656.
185. Haley D.A., Horwitz J., Stewart P.L. The small heat-shock protein, αB-crystallin, has a variable quaternary structure. J. Mol. Biol. 1998, 277:27-35.
186. Wilhelmus M.M.M., Otte-Höller I., Wesseling P., De Waal R.M.W., Boelens W.C., Verbeek M.M. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathol. Appl. Neurobiol. 2006, 32:119-130.
187. Quraishe S., Asuni A., Boelens W.C., O'Connor V., Wyttenbach A. Expression of the small heat shock protein family in the mouse CNS: differential anatomical and biochemical compartmentalization. Neuroscience 2008, 153:483-491.
188. Plumier J.-C.L., Hopkins D.A., Robertson H.A., Currie R.W. Constitutive expression of the 27-kDa heat shock protein (Hsp27) in sensory and motor neurons of the rat nervous system. J. Comp. Neurol. 1997, 384:409-428.
189. Kato K., Hasegawa K., Goto S., Inaguma Y. Dissociation as a result of phosphorylation of an aggregated form of the small stress protein, Hsp27. J. Biol. Chem. 1994, 269:11274-11278.
190. Renkawek K., Stege G.J.J., Bosman G.J.C.G.M. Dementia, gliosis and expression of the small heat shock proteins Hsp27 and alphaB-crystallin in Parkinson's disease. Neuroreport August 1999, 10:2273-2276.
191. Zhang Y., James M., Middleton F.A., Davis R.L. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 137B:5-16.
192. Waudby C.A., Knowles T.P.J., Devlin G.L., Skepper J.N., Ecroyd H., Carver J.A., Welland M.E., Christodoulou J., Dobson C.M., Meehan S. The interaction of αB-crystallin with mature α-synuclein amyloid fibrils inhibits their elongation. Biophys. J. 2010, 98:843-851.
193. Wang J., Martin E., Gonzales V., Borchelt D.R., Lee M.K. Differential regulation of small heat shock proteins in transgenic mouse models of neurodegenerative diseases. Neurobiol. Aging 2008, 29:586-597.
194. Zourlidou A., Payne Smith M.D., Latchman D.S. Hsp27 but not Hsp70 has a potent protective effect against α-synuclein-induced cell death in mammalian neuronal cells. J. Neurochem. 2004, 88:1439-1448.
195. Tue N.T., Shimaji K., Tanaka N., Yamaguchi M. Effect of alphaB-crystallin on protein aggregation in Drosophila. J. Biomed. Biotechnol. 2012, 2012:252049.
196. Ecroyd H., Meehan S., Horwitz J., Aquilina J.A., Benesch J.L.P., Robinson C., Macphee C., Carver J.A. Mimicking phosphorylation of αB-crystallin affects its chaperone activity. Biochem. J. 2007, 401:129-141.
197. Knowles T.P.J., Waudby C.A., Devlin G.L., Cohen S.I.A., Aguzzi A., Vendruscolo M., Terentjev E.M., Welland M.E., Dobson C.M. An analytical solution to the kinetics of breakable filament assembly. Science 2009, 326:1533-1537.
198. Esposito G., Garvey M., Alverdi V., Pettirossi F., Corazza A., Fogolari F., Polano M., Mangione P.P., Giorgetti S., Stoppini M., Rekas A., Bellotti V., Heck A.J.R., Carver J.A. Monitoring the interaction between β2-microglobulin and the molecular chaperone αB-crystallin by NMR and mass spectrometry: αB-crystallin dissociates β2-microglobulin oligomers. J. Biol. Chem. 2013, 288:17844-17858.
199. Forloni G., Bertani I., Calella A.M., Thaler F., Invernizzi R. α-Synuclein and Parkinson's disease: selective neurodegenerative effect of α-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann. Neurol. 2000, 47:632-640.
200. Freundt E.C., Maynard N., Clancy E.K., Roy S., Bousset L., Sourigues Y., Covert M., Melki R., Kirkegaard K., Brahic M. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann. Neurol. 2012, 72:517-524.
201. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., Lee V.M.-Y. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
202. Desplats P., Lee H.J., Bae E.J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13010-13015.
203. Volpicelli-Daley L.A., Luk K.C., Patel T.P., Tanik S.A., Riddle D.M., Stieber A., Meaney D.F., Trojanowski J.Q., Lee V.M.Y. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72:57-71.
204. Zhou W., Hurlbert M.S., Schaack J., Prasad K.N., Freed C.R. Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 2000, 866:33-43.
205. Zhou W., Schaack J., Zawada W.M., Freed C.R. Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 2002, 926:42-50.
206. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 2000, 20:6048-6054.
207. Matsuzaki M., Hasegawa T., Takeda A., Kikuchi A., Furukawa K., Kato Y., Itoyama Y. Histochemical features of stress-induced aggregates in α-synuclein overexpressing cells. Brain Res. 2004, 1004:83-90.
208. McLean P.J., Kawamata H., Hyman B.T. α-Synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 2001, 104:901-912.
209. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J., Margolis R.L., Troncoso J.C., Lanahan A.A., Worley P.F., Dawson V.L., Dawson T.M., Ross C.A. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 1999, 22:110-114.
210. Bertoncini C.W., Jares-Erijman E.A., Jovin T.M., Klement R., Roberti M.J. Fluorescence imaging of amyloid formation in living cells by a functional, tetracysteine-tagged alpha-synuclein. Nat. Methods 2007, 4:345-351.
211. Wan O.W., Chung K.K.K. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PLoS ONE 2012, 7:e38545.
212. Klucken J., Shin Y., Masliah E., Hyman B.T., McLean P.J. Hsp70 reduces α-synuclein aggregation and toxicity. J. Biol. Chem. 2004, 279:25497-25502.
213. Mehlen P., Preville X., Chareyron P., Briolay J., Klemenz R., Arrigo A.P. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J. Immunol. 1995, 154:363-374.
214. An J.J., Lee Y.P., Kim S.Y., Lee S.H., Lee M.J., Jeong M.S., Kim D.W., Jang S.H., Yoo K.-Y., Won M.H., Kang T.-C., Kwon O.-S., Cho S.-W., Lee K.S., Park J., Eum W.S., Choi S.Y. Transduced human PEP-1-heat shock protein 27 efficiently protects against brain ischemic insult. FEBS J. 2008, 275:1296-1308.
215. Préville X., Salvemini F., Giraud S., Chaufour S., Paul C., Stepien G., Ursini M.V., Arrigo A.P. Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Exp. Cell Res. 1999, 247:61-78.
216. Acunzo J., Katsogiannou M., Rocchi P. Small heat shock proteins HSP27 (HspB1), αB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int. J. Biochem. Cell Biol. 2012, 44:1622-1631.
217. Kamradt M.C., Chen F., Cryns V.L. The small Heat shock protein αB-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J. Biol. Chem. 2001, 276:16059-16063.
218. Voss O.H., Batra S., Kolattukudy S.J., Gonzalez-Mejia M.E., Smith J.B., Doseff A.I. Binding of caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J. Biol. Chem. 2007, 282:25088-25099.
219. Bruey J.M., Ducasse C., Bonniaud P., Ravagnan L., Susin S.A., Diaz-Latoud C., Gurbuxani S., Arrigo A.P., Kroemer G., Solary E., Garrido C. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2000, 2:645-652.
220. Charette S.J., Lavoie J.N., Lambert H., Landry J. Inhibition of Daxx-mediated apoptosis by Heat shock protein 27. Mol. Cell. Biol. 2000, 20:7602-7612.
221. Mao Y.W., Liu J.P., Xiang H., Li D.W. Human alphaA- and alphaB-crystallins bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine-induced apoptosis. Cell Death Differ. 2004, 11:512-526.
222. Fernagut P.-O., Chesselet M.-F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 2004, 17:123-130.
223. Kahle P.J. Alpha-synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:87-95.
224. Crabtree D.M., Zhang J. Genetically engineered mouse models of Parkinson's disease. Brain Res. Bull. 2012, 88:13-32.
225. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8968-8973.
226. Lelan F., Boyer C., Thinard R., Remy S., Usal C., Tesson L., Anegon I., Neveu I., Damier P., Naveilhan P., Lescaudron L. Effects of human alpha-synuclein A53T-A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease. Park. Dis. 2011, 2011:987084.
227. Lakso M., Vartiainen S., Moilanen A.M., Sirvio J., Thomas J.H., Nass R., Blakely R.D., Wong G. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 2003, 86:165-172.
228. Kuwahara T., Koyama A., Gengyo-Ando K., Masuda M., Kowa H., Tsunoda M., Mitani S., Iwatsubo T. Familial Parkinson mutant α-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 2006, 281:334-340.
229. Cao P., Yuan Y., Pehek E.A., Moise A.R., Huang Y., Palczewski K., Feng Z. Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans. PLoS ONE 2010, 5:e9312.
230. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
231. Mizuno H., Fujikake N., Wada K., Nagai Y. Alpha-synuclein transgenic Drosophila as a model of Parkinson's disease and related synucleinopathies. Park. Dis 2010, 2011:212706.